Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
79.52
-3.66 (-4.40%)
Nov 17, 2026, 3:00 PM CST

SHA:688266 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,753810.19531.53383.56301.67188.99
Other Revenue
0.30.31.432.880.631.37
1,754810.48532.95386.44302.31190.36
Revenue Growth
136.24%52.07%37.91%27.83%58.81%588.19%
Cost of Revenue
131.9181.9737.7231.4227.537.1
Gross Profit
1,622728.51495.23355.02274.78183.26
Selling, General & Admin
644.36538.62328.9264.84312.66216.96
Research & Development
451.8429.91388496.33497.73509.39
Other Operating Expenses
13.572.41-6.87-9.341.05-40.46
Operating Expenses
1,112971.36712.25752.47812.83689.18
Operating Income
509.56-242.84-217.02-397.45-538.06-505.91
Interest Expense
-22.09-24.2-28.89-22.55-12.03-4.42
Interest & Investment Income
49.9855.4861.2345.3132.6951.04
Currency Exchange Gain (Loss)
-0.9-0.9-0.01-0.03-0.160.8
Other Non Operating Income (Expenses)
-12.31-0.08-1.74-2.88-3.48-8.39
EBT Excluding Unusual Items
524.24-212.54-186.45-377.6-521.04-466.88
Gain (Loss) on Sale of Investments
3.890.843.928.732.631.74
Gain (Loss) on Sale of Assets
-0.020--0.02-
Asset Writedown
-4.54---0.28-0.11-0.01
Other Unusual Items
43.0243.0527.4870.0730.55-
Pretax Income
566.59-168.65-155.05-299.08-487.95-465.15
Income Tax Expense
-2.14-3.53-4.75-3.95-2.45-3.16
Earnings From Continuing Operations
568.74-165.13-150.3-295.13-485.51-461.99
Minority Interest in Earnings
-2.1812.4716.5528.1810.99
Net Income
568.74-162.95-137.83-278.58-457.33-451
Net Income to Common
568.74-162.95-137.83-278.58-457.33-451
Net Income Growth
------
Shares Outstanding (Basic)
261263265256239240
Shares Outstanding (Diluted)
261263265256239240
Shares Change
-2.07%-0.85%3.71%6.74%-0.19%2.20%
EPS (Basic)
2.18-0.62-0.52-1.09-1.91-1.88
EPS (Diluted)
2.18-0.62-0.52-1.09-1.91-1.88
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
699.61-210.25-57.49-295.35-458.97-525.36
Free Cash Flow Per Share
2.68-0.80-0.22-1.16-1.92-2.19
Gross Margin
92.48%89.89%92.92%91.87%90.89%96.27%
Operating Margin
29.06%-29.96%-40.72%-102.85%-177.98%-265.77%
Profit Margin
32.43%-20.11%-25.86%-72.09%-151.28%-236.92%
Free Cash Flow Margin
39.90%-25.94%-10.79%-76.43%-151.82%-275.98%
EBITDA
550.54-200.89-173.76-355.54-485.56-463.65
EBITDA Margin
31.40%-24.79%-32.60%-92.00%-160.62%-243.57%
D&A For EBITDA
40.9841.9643.2641.9152.542.26
EBIT
509.56-242.84-217.02-397.45-538.06-505.91
EBIT Margin
29.06%-29.96%-40.72%-102.85%-177.98%-265.77%
Revenue as Reported
1,754810.48532.95386.44302.31190.36
Advertising Expenses
-3.40.391.3675.9533.8